Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

January 8, 2026

Study Completion Date

January 8, 2028

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

Treatment group

Chidamide+XELOX + Bevacizumab+PD-1

DRUG

Standard-of-care control group

XELOX + Bevacizumab+PD-1

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER